Skip to content

Study · Randomized controlled trial · n = 106 · 2019

7 results

Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism.

Owada K, Okada T, Munesue T, Kuroda M, Fujioka T, Uno Y, Matsumoto K, Kuwabara H, Mori D, Okamoto Y, Yoshimura Y, Kawakubo Y and 17 more

Show all authors

Arioka Y, Kojima M, Yuhi T, Yassin W, Kushima I, Benner S, Ogawa N, Kawano N, Eriguchi Y, Uemura Y, Yamamoto M, Kano Y, Kasai K, Higashida H, Ozaki N, Kosaka H, Yamasue H

Brain : a journal of neurology1 Jul 2019Cited by 24 (Europe PMC)

PMID31096266 (opens in a new tab)DOI10.1093/brain/awz126 (opens in a new tab)PepBankPUB-31096266
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adult men with autism spectrum disorder, repeated oxytocin decreased the natural logarithm of mode of neutral facial expression versus placebo in the confirmatory trial (effect size -0.41, P < 0.001).

    In plain wordsIn adult men with autism, repeated oxytocin reduced a measure of neutral facial expression more than placebo in a larger trial.

    Peptide
    Oxytocin
    Outcome
    DecreaseNatural log of mode of neutral facial expression, confirmatory trial
    Study

    n = 106

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    effect size
    −0.41 effect size
    confirmatory trial

    Source sentences

    Summary
    The current results revealed that oxytocin consistently and significantly decreased the increased natural logarithm of mode on the probability density function of neutral facial expression compared with placebo in exploratory (effect-size, -0.57; 95% CI, -1.27 to 0.13; P = 0.023) and confirmatory tr…
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adult men with autism spectrum disorder, repeated oxytocin decreased the natural logarithm of mode of neutral facial expression versus placebo in the exploratory trial (effect size -0.57, P = 0.023).

    In plain wordsIn adult men with autism, repeated oxytocin reduced a measure of neutral facial expression more than placebo in a small trial.

    Peptide
    Oxytocin
    Outcome
    DecreaseNatural log of mode of neutral facial expression, exploratory trial
    Study

    n = 18

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    effect size
    −0.57 effect size
    exploratory trial

    Source sentences

    Summary
    oxytocin consistently and significantly decreased the increased natural logarithm of mode on the probability density function of neutral facial expression compared with placebo in exploratory (effect-size, -0.57; 95% CI, -1.27 to 0.13; P = 0.023
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In the confirmatory trial, a significant interaction between time and the efficacy of oxytocin on neutral facial expression was found (P < 0.001).

    In plain wordsIn adult men with autism, the effect of oxytocin on facial expression changed over the weeks of treatment.

    Peptide
    Oxytocin
    Outcome
    MixedTime-course interaction of oxytocin efficacy
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In the confirmatory trial, oxytocin had maximum efficacy at 2 weeks (Cohen's d -0.78).

    In plain wordsIn adult men with autism, oxytocin had its largest effect on facial expression at 2 weeks.

    Peptide
    Oxytocin
    Outcome
    DecreaseNeutral facial expression at 2 weeks
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    Cohen's d
    −0.78 d
    2 weeks

    Source sentences

    Summary
    maximum efficacy at 2 weeks (P < 0.001, Cohen's d = -0.78; 95% CI, -1.21 to -0.35)
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In the confirmatory trial, the efficacy of oxytocin deteriorated at 4 weeks (Cohen's d -0.46, P = 0.042).

    In plain wordsIn adult men with autism, the effect of oxytocin on facial expression was smaller at 4 weeks.

    Peptide
    Oxytocin
    Outcome
    DecreaseNeutral facial expression at 4 weeks
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    Cohen's d
    −0.46 d
    4 weeks

    Source sentences

    Summary
    deterioration of efficacy at 4 weeks (P = 0.042, Cohen's d = -0.46; 95% CI, -0.90 to -0.01)
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In the confirmatory trial, the efficacy of oxytocin at 6 weeks was not significant (P = 0.10, Cohen's d -0.35).

    In plain wordsIn adult men with autism, the effect of oxytocin on facial expression at 6 weeks was not significant.

    Peptide
    Oxytocin
    Outcome
    No significant changeNeutral facial expression at 6 weeks
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    Cohen's d
    −0.35 d
    6 weeks

    Source sentences

    Summary
    6 weeks (P = 0.10, Cohen's d = -0.35; 95% CI, -0.77 to 0.08)
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…
  7. 07HumanRandomized controlled trialEfficacy outcome

    In the confirmatory trial, the efficacy of oxytocin was preserved 2 weeks after treatment, at 8 weeks (Cohen's d -1.24, P < 0.001).

    In plain wordsIn adult men with autism, the effect of oxytocin on facial expression was still present 2 weeks after treatment ended.

    Peptide
    Oxytocin
    Outcome
    DecreaseNeutral facial expression at 8 weeks (2 weeks post-treatment)
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    Cohen's d
    −1.24 d
    8 weeks

    Source sentences

    Summary
    efficacy was preserved at 2 weeks post-treatment (i.e. 8 weeks) (P < 0.001, Cohen's d = -1.24; 95% CI, -1.71 to -0.78)
    1 context sentence
    Summary · context
    We examined videos recorded during semi-structured social interaction administered as the primary outcome in single-site exploratory (n = 18, crossover within-subjects design) and multisite confirmatory (n = 106, parallel-group design), double-blind, placebo-controlled 6-week trials of repeated intr…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.